<DOC>
	<DOCNO>NCT01697436</DOCNO>
	<brief_summary>This four-period , single-center , open-label , single-dose , randomize , cross-over study ass bioequivalence safety oral solution Copegus ( ribavirin ) compare Copegus tablet healthy adult volunteer . Volunteers randomize one four sequence receive treatment feed fasted condition .</brief_summary>
	<brief_title>A Bioequivalence Study Oral Solution Copegus ( Ribavirin ) Compared Copegus Tablets</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult healthy volunteer Able participate willing give inform consent comply study restriction . Negative urine pregnancy test ( woman childbearing potential ) document screen within 24hour period prior dose test drug All male subject female partner childbearing potential must agree use two reliable form contraception , one must physical barrier method , study 6 month thereafter Female subject must postmenopausal surgically sterile must agree use two reliable form contraception one must physical barrier method , treatment 6 month thereafter Body mass index ( BMI ) &lt; 30 kg/m2 Pregnant lactate woman male partner female pregnant lactate Positive test drug abuse screen within 24hour period prior dose test drug . History ( within 3 month screen ) alcohol consumption exceed 2 standard unit per day average ( 1 standard unit = 10 gram alcohol ) . Alcohol consumption prohibit least 48 hour screen least 48 hour Day 1 end study Confirmed systolic blood pressure ( SBP ) &gt; 140 &lt; 90 mm Hg , diastolic blood pressure ( DBP ) &gt; 90 &lt; 50 mm Hg Resting pulse rate &gt; 90 &lt; 45 beat per minute History symptom significant disease include ( limited ) hematological , neurological , psychiatric , cardiovascular , respiratory , gastrointestinal , hepatic , renal disorder History active malignancy within last 5 year , exception localize situ carcinoma skin ( e.g. , skin basal squamous cell carcinoma ) Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) , human immunodeficiency virus antibody ( HIV Ab ) screening Use medication ( prescription overthecounter , vitamin , mineral , herbal , dietary supplement within 7 day , le 5 halflives ( whichever longer ) prior randomization . Exceptions acetaminophen ( 2 g/day ) , ibuprofen ( 1 g/day ) , hormonal contraceptive . Clinically significant abnormality laboratory test result Participation investigational drug study within 60 day investigational device study within 30 day prior screen Donation blood 500 mL 3 month prior screen end study ; donation plasma 7 day prior screen end study Concomitant disease condition could interfere , treatment might interfere , conduct study would , opinion Investigator , pose unacceptable risk subject study Smoker 10 cigarette per day prior screen use tobacco product equivalent 10 cigarette per day Clinically significant abnormality predose rest electrocardiogram Any confirm significant allergic reaction RBV know potential allergy hypersensitivity nonactive ingredient study drug ( nonactive hay fever acceptable ) Individuals receive ribavirin therapy within 6 month prior study initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>